Physician profile
Ling Zhang
NPI 1710277678
$9,113.44
in general payments reported to CMS, 2019-2025
47 companies · $4,447 in 2025
The $4,447 reported for 2025 was more than what 84% of Neurology (Psychiatry & Neurology) providers received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $31.60 · 2020: $31.08 · 2021: $42.38 · 2022: $115 · 2023: $2,100 · 2024: $2,346 · 2025: $4,447.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $8,885 · Education: $8.75.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $8,885.12 |
| Education | $8.75 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $736.08 | 2019-2025 | Rystiggo, Fintepla, Briviact |
| Abbvie INC. | $695.44 | 2023-2025 | Qulipta, Botox, Ubrelvy |
| Biogen, INC. | $694.00 | 2023-2025 | Vumerity, Tysabri, Leqembi |
| Novartis Pharmaceuticals Corporation | $682.76 | 2023-2025 | |
| Argenx US, INC. | $628.91 | 2023-2025 | Vyvgart Hytrulo, Vyvgart |
| Sk Life Science, INC. | $480.55 | 2023-2025 | Xcopri |
| Eisai INC. | $408.28 | 2023-2025 | |
| Emd Serono, INC. | $404.94 | 2023-2025 | Mavenclad |
| Neurocrine Biosciences, INC. | $400.50 | 2023-2025 | Ingrezza |
| Alexion Pharmaceuticals, INC. | $375.79 | 2024-2025 | Ultomiris, Koselugo |
| Pfizer INC. | $339.63 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $296.47 | 2024-2025 | Rexulti, Nuedexta |
| Lilly USA, LLC | $282.18 | 2022-2025 | Emgality, Kisunla, Amyvid |
| Amneal Pharmaceuticals LLC | $272.52 | 2025 | Crexont |
| Medtronic, INC. | $264.82 | 2024 | Percept PC Brainsense |
Show all 47 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $229.96 | 2024-2025 | Austedo Xr, Austedo Xr |
| Alnylam Pharmaceuticals INC. | $225.40 | 2023 | Onpattro |
| Abbott Laboratories | $198.90 | 2020-2023 | Infinity |
| Lundbeck LLC | $187.19 | 2025 | Vyepti |
| Amgen INC. | $180.96 | 2025 | Uplizna |
| Kyowa Kirin, INC. | $153.80 | 2023-2024 | Nourianz |
| Merz Pharmaceuticals, LLC | $114.13 | 2023-2025 | Xeomin, Inbrija |
| Celgene Corporation | $85.01 | 2025 | Zeposia |
| Acorda Therapeutics, INC | $77.95 | 2023 | Inbrija, Ampyra |
| Livanova USA, INC. | $66.66 | 2024-2025 | Vns Therapy Sentiva Model 1000 Generator |
| Tonix Medicines, INC. | $58.14 | 2025 | Zembrace Symtouch, Tonmya |
| Genzyme Corporation | $52.07 | 2025 | |
| Tg Therapeutics, INC. | $50.73 | 2023-2025 | |
| Janssen Biotech, INC. | $45.44 | 2025 | |
| Genentech USA, INC. | $42.43 | 2023-2024 | Ocrevus, Enspryng |
| Sunovion Pharmaceuticals INC. | $42.38 | 2021 | |
| Mallinckrodt Hospital Products INC. | $31.75 | 2025 | Acthar |
| Vanda Pharmaceuticals INC. | $31.46 | 2025 | Ponvory |
| Amylyx Pharmaceuticals, INC. | $31.33 | 2023 | Relyvrio |
| Ipsen Biopharmaceuticals, INC | $30.64 | 2024 | Dysport |
| Horizon Therapeutics Plc | $24.39 | 2023 | Uplizna |
| Aucta Pharmaceuticals, INC. | $23.00 | 2025 | Motpoly Xr |
| Tanabe Pharma America, INC. | $19.83 | 2023 | |
| Xeris Pharmaceuticals, INC. | $19.46 | 2025 | Keveyis |
| Scilex Pharmaceuticals INC. | $19.24 | 2025 | |
| Forte Bio-Pharma LLC | $18.30 | 2025 | Tanlor |
| Mdd US Operations, LLC | $18.01 | 2024 | Gocovri |
| Philips North America LLC | $16.35 | 2025 | Ambulatory Monitoring & Diagnostics Undivided |
| Acadia Pharmaceuticals INC | $15.68 | 2025 | Nuplazid |
| Astrazeneca Pharmaceuticals LP | $15.04 | 2025 | Wainua |
| Sumitomo Pharma America, INC. | $12.93 | 2023 | Aptiom |
| Harmony Biosciences LLC | $12.01 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ling Zhang listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.